Broad-Based Growth Reflects Strong Seasonal Demand for Fresh, Flavor-Enhancing Herbs Across Retail NetworkBELVIDERE, NJ, May 28, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced that the Company estimates a more than 25% year-over-year increase in preliminary herb sales during the key Easter holiday period1, based ...

Group 1 - Nykredit Realkredit A/S has published supplement no 1 to its Base Prospectus dated 8 May 2025 for the issuance of European covered bonds and bonds under the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds Act [1] - The Base Prospectus and the supplement are available for download in both Danish and English, with the Danish text prevailing in case of discrepancies [2] - Contact information for inquiries is provided, including Morten Bækmand Nielsen, Head of ALM & Investor Relations, and Birna Arnbjarnardóttir, Attorney-at-Law [3] Group 2 - The supplement to the Base Prospectus includes details relevant to investors regarding the issuance of premium European covered bonds [1] - The documents can be accessed on Nykredit's official website [2] - The publication of the supplement indicates ongoing activities in the bond issuance market by Nykredit Realkredit A/S [1]

Core Points - The shareholders of UAB "Atsinaujinančios energetikos investicijos" approved the extension of the Company's term of operation by an additional two years [1] - The decision was made during an extraordinary general meeting held on 16 May 2025, with more than a 9/10 majority of votes cast [1] - The new term of operation is now extended until 5 February 2028 [1] Company Information - The Company is a closed-end investment company intended for informed investors [1] - Mantas Auruškevičius is the contact person for further information regarding the Company [2]

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully developed a new recombinant spider silk parental line aimed at large-scale commercial production, enhancing its capacity to meet material demand and scale inventory [1][2][3] Company Developments - The newly developed strain marks the third commercial production line created by the company as part of its strategy to expand output capacity and fulfill current material requests while building inventory for future sales [2][3] - The new production strain is a key component of the company's roadmap established in 2024, facilitating a transition to a full double hybrid production system, which is expected to yield higher silk outputs, improve colony resilience, and lower production costs [3][4] Strategic Goals - The company aims to enhance scalability, efficiency, and product consistency through the implementation of double hybrid crosses in its production platform, which is a significant step towards mainstream market integration of spider silk technology [4][3] - Kraig Labs is focused on transitioning from pilot operations to full-scale manufacturing, reinforcing its commitment to building a robust and scalable production system [4]

MONTREAL, May 28, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. ("HPQ" or the "Company") (TSX- V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is pleased to inform shareholders that the leading global fumed silica manufacturer—under the LOI announced on July 9, 2024—has requested to receive samples of the material earlier than initially scheduled. This follows HPQ's May 21, 2025, press release confirming the independent validation ...

Fiscal 2024 Q4 2024 MONTREAL, May 28, 2025 (GLOBE NEWSWIRE) -- DAVIDsTEA Inc. (TSX-Venture: DTEA) ("DAVIDsTEA" or the "Company"), a leading tea merchant in North America, announced today its fourth quarter and full-year results for the period ended February 1, 2025 ("Fiscal 2024"). "Fiscal 2024 proved to be a positive turnaround year for DAVIDsTEA, marked by incremental sales growth, gross profit improvement and positive cash flow from operations," said Sarah Segal, Chief Executive Officer and Chief Brand O ...

Expanding patent portfolio reinforces the Company's commitment to wound care innovation, with 55 issued patents and 52 pending applications Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, a ...

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T. Investor Contact: Christina Tartaglia Precision AQ 332.322.7430 Christina.tartaglia@precisionaq.com Media Contact: Peg Rusconi 6 ...

MONTREAL, May 28, 2025 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX.V: HAR) ("Harfang" or the "Company") is pleased to announce additional high-grade intercepts and the second batch of results from the 2025 winter diamond drill program ("Winter Drilling"). Winter Drilling focused on the Koval patented claims at its recently acquired and wholly owned Sky Lake Gold Project located in Ontario's Pickle Lake Gold District (Figure 1). The Company has intersected a high-grade mineralized interval interpreted ...

About 303 Study 303 Study is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical C ...